TTrialPathMatch Me to Trials
← Back to trials
RecruitingGlioblastomaAstrocytomaVenous Thromboembolism

Venous Thromboembolism Prevention in Outpatients With Glioma

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.

Sponsor: University of Vermont Medical Center

You may qualify if…

  • ✓ Histologic diagnosis of malignant glioma, World Health Organization (WHO) grade 4, including glioblastoma and astrocytoma, based on recent biopsy or resection.
  • ✓ Age 18 and old
  • ✓ Karnofsky performance status (KPS) 60-100
  • ✓ Acceptable labs, including platelets of greater than or equal to 100,000, glomerular filtration rate (GFR) greater than or equal to 25.
  • ✓ Ability to provide informed consent.
  • ✓ Planning for treatment with radiation and chemotherapy.

You may not qualify if…

  • ✕ Evidence of deep venous thrombosis (DVT), pulmonary embolism (PE), or cerebral vein thrombosis (CVT) within 6 months prior to enrollment on the study.
  • ✕ Pregnancy.
  • ✕ Significant bleeding risk including: history of symptomatic intracranial hemorrhage, active bleeding at time of study registration, clinically significant bleeding within 14 days of study registration, intracranial trauma in the past 6 months, including stroke or traumatic brain injury, major surgery or major procedure within 48 hours.
  • ✕ Allergy to apixaban or contraindication to prophylactic anticoagulation. Contraindications include patients who are currently on unfractionated heparin, low molecular weight heparin, heparin derivatives (examples: fondaparinux), or other direct oral anticoagulants (examples: dabigatran, edoxaban, rivaroxaban), who are either unable or unable to discontinue these agents in favor of the investigational drug. Apixaban is also contraindicated in patients who are on strong CYP3A4 inhibitor and P-glycoprotein inhibitors.
  • ✕ Indication for full anticoagulation (i.e. atrial fibrillation, mechanical valve, etc.).
  • ✕ Estimated life expectancy of \<3 months.

Where it's recruiting

Vermont

Burlington

Source: ClinicalTrials.gov · NCT05683808 · last updated 2026-01-30